## **IN THE CLAIMS:**

This listing of claims will replace all prior versions and listing of claims in the application. Listing of the claims:

Claim 1 (currently amended): A compound of formula (I) or a pharmaceutically acceptable salt-or-solvate thereof:

$$\begin{array}{c|c}
R^{1} & O \\
R^{2} & S = O
\end{array}$$

$$\begin{array}{c|c}
R^{3} & N & R^{6} \\
R^{4} & N & R^{5}
\end{array}$$
(I)

in which:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, <u>chlorine</u>, <u>fluorine</u> <u>halogen</u>, <u>or</u> cyano, <u>CF<sub>3</sub>, OCF<sub>3</sub>, OCF<sub>4</sub>, alkyl</u>;

R<sup>4</sup> is halogen, CO<sub>2</sub>R<sup>12</sup>; or C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;

C<sub>3-6</sub> alkenyloxy or C<sub>3-6</sub> alkynyloxy where either may be optionally substituted with hydroxy or NR<sup>14</sup>R<sup>15</sup>;

OC<sub>1-6</sub> alkyl-X-C<sub>1-6</sub> alkyl where the alkyl groups may form a 3-6 membered saturated ring;

OC<sub>1-6</sub> alkylR<sup>11</sup>, or OC<sub>2-6</sub> alkyl-X-R<sup>11</sup> where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>; SR<sup>13</sup>; S(O)<sub>2</sub>R<sup>13</sup>; S(O)R<sup>13</sup> or COR<sup>13</sup>;

OC<sub>1-6</sub> alkylR<sup>16</sup>;

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, cyano, halogen, CO<sub>2</sub>R<sup>12</sup>, CONR<sup>14</sup>R<sup>15</sup>; C<sub>1-6</sub> alkyl optionally substituted by hydroxy, NR<sup>14</sup>R<sup>15</sup>, or 1-3 fluorines;

C<sub>1-6</sub> alkylR<sup>14</sup> or XCH(R<sup>14</sup>)C<sub>1-6</sub> alkyl or XCH(R<sup>16</sup>)C<sub>1-6</sub> alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR<sup>14</sup>R<sup>15</sup>;

NR<sup>14</sup>R<sup>15</sup>; N(R<sup>14</sup>)R<sup>14</sup>; X-(CH<sub>2</sub>)qNR<sup>14</sup>R<sup>15</sup>; (CH<sub>2</sub>)nNR<sup>14</sup>R<sup>15</sup>; NHC(O)C<sub>1-6</sub> alkyl optionally substituted by one or more hydroxy groups,

 $C_{3-6}$  alkynyl or  $C_{3-6}$  alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =0;

 $R^{++}; X-R^{++}; X-R^{12}; X-C_{1-6}alkylR^{+6}; X-R^{+6}; X-(CH_2)nCO_2R^{12}; X-(CH_2)nCONR^{14}R^{15}; X-(CH_2)nR^{++}; X-(CH_2)nCN; X-(CH_2)qOR^{12}; (CH_2)nOR^{12}; (CH_2)n-X-R^{++}; X-(CH_2)qNHC(O)NHR^{12}; X-(CH_2)qNHC(O)R^{12}; X-(CH_2)qNHS(O)_2R^{12}; X-(CH_2)qNHS(O)_2R^{12}; X-(CH_2)qNHS(O)_2R^{12}; X-C_{3-6}alkenyl; X-C_{3-6}alkynyl;$ 

n is 1,2,3,4 or 5;

q is 2, 3, 4, 5 or 6;

 $X \text{ is } NR^{13}, O, S, S(O), S(O)_2;$ 

 $R^{++}$  is an aryl-group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen,  $C(O)NR^{++}R^{+5}$ ,  $C(O)OR^{+2}$ , hydroxy,  $C(O)R^{+2}$ , hydroxy,  $C(O)R^{+3}$ ,  $C(O)R^{+3}$ ,  $C(O)R^{+3}$ ,  $C(O)R^{+4}R^{+5}$ ,  $C(CH_2)R^{+4}R^{+5}$ ,  $C(C)R^{+4}R^{+5}$ ,  $C(C)R^{+4}R^{+$ 

R<sup>12</sup> and R<sup>13</sup> are independently hydrogen or C<sub>1-6</sub> alkyl where the alkyl group may be substituted with 1-3 fluorine atoms; or may form a saturated 3-6 membered ring; and

R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, <del>C<sub>3-6</sub> cycloalkyl</del> or (CH<sub>2</sub>)qOH<sub>2</sub>,

or R<sup>14</sup> and R<sup>15</sup> together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl-OH, or hydroxy; and

R<sup>16</sup> is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, eyano, halogen and =0.

## provided that:

- •when R<sup>4</sup> is halogen or C<sub>1-4</sub>alkoxy and R<sup>5</sup> is hydrogen, halogen, C<sub>1-4</sub>alkyl, C<sub>1-2</sub>alkoxy, C<sub>1-2</sub>alkylthio, trifluoromethyl or ethynyl and when one R<sup>1</sup>, R<sup>2</sup>, or R<sup>3</sup> is C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy and is meta to the sulphonamide group then the group ortho to both the sulphonamide group and the C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy group is not hydrogen,
- •when R<sup>4</sup> is halogen or C<sub>1-4</sub>alkoxy and R<sup>5</sup> is hydrogen, halogen, C<sub>1-4</sub>alkyl, C<sub>1-2</sub>alkoxy, C<sub>1-2</sub>alkoxy, C<sub>1-2</sub>alkylthio, trifluoromethyl, or ethynyl and when one of R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> is C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy and is ortho to the sulphonamide group then the group ortho to the C<sub>1-6</sub>Alkyl or C<sub>1-6</sub>alkoxy and also meta to the sulphonamide group is not hydrogen,
- •when two of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> are hydrogen and the other is a methyl group para to the sulphonamide and R<sup>4</sup> is methoxy then R<sup>5</sup> is not hydrogen or bromo, and
- •when R<sup>5</sup> is methyl and R<sup>6</sup> is methoxy and one of R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> is brome or iode and the other two are both hydrogen, then the brome or iode group is not ortho to the sulphonamide group.

Claim 2 (currently amended): A compound according to claim 1 in which one of R<sup>1</sup> and ,-R<sup>2</sup> are chloro at the 2- and 3-positions of the phenyl ring and R<sup>3</sup> is hydrogen-and the other is chloro, brome or methyl.

Claim 3 (currently amended): A compound according to claim 1 or 2 in which R<sup>4</sup> is C<sub>1-6</sub> alkoxy-such as methoxy, 2-furanylmethoxy, bromo, chloro, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, 2-(1-imidazolyl)ethoxy, (2-methyl-4-oxazolyl)methoxy and 4-methoxyphenylmethoxy.

Claim 4 (currently amended): A compound according to <u>claim 1 any one of claims 1 to</u> 3-in which R<sup>5</sup> is hydrogen, halogen-such as bromo and chloro, phenyl, \_Cl<sub>1-6</sub> alkyl, such as methyl, CH<sub>2</sub>OH, cyano and or 2-aminoethanethiol. 2-aminothanethiol

Claim 5 (currently amended): A compound according to claim 1 any one of claims 1 to 3 in which R<sup>6</sup> is hydrogen, C<sub>1-6</sub> alkyl, CH<sub>2</sub>OH and or halogen.

Claim 6 (currently amended): A compound according to claim 1 in which is: 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,3,4-tifluorobenzenesulphonamide

Page 7

```
3-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
```

- 2,3-Dichloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- *N*-(5-Bromo-3-methoxy-2-pyrazinyl)-2,5-dichlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,5-dichlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-3,4-dichlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-4-chlorobenzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-chlorobenzenesulphonamide
- N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-fluorobenzenesulphonamide
- N-(3-Methoxy-5-methyl-2-pyrazinyl)benzenesulphonamide
- N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-iodobenzenesulphonamide
- N-(3-Methoxy-5-methyl-2-pyrazinyl)-3-fluorobenzenesulphonamide
- 2-[[(3-Methoxy-5-methyl-2-pyrazinyl)amino]sulphonyl]benzonitrile
- N-(5-Bromo-3-methoxy-2-pyrazinyl)benzenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)2-iodobenzenesulphonamide
- 2,3-Dichloro-N-[3-(2-furanylmethoxy)-5-methyl-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-methyl-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-methyl-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N [5-methyl-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[5-methyl-3-(3-pyridinylmethoxy) 2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-methyl-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[5-methyl-3-(3-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3 Dichloro N-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
- N-[5-Bromo-3-(2-pyrazinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- *N* [5-Bromo-3-(1-methyl-6-oxo-1,6-dihydro-3-pyridinylmethoxy)-2-pyrazinyl] 2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(3-pyridazinyllmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-15-Bromo-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2.3-dichlorobenzenesulphonamide

```
N-[5-Chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
```

- N-[5-Chloro-3-(5-pyrimidinylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- 2-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benezenesulphonamide
- 4-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)benezenesulphonamide
- N-(6-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenezenesulphonamide
- N-(6-Chloro-3-methoxy-2-pyrazinyl)-3,4-dichlorobenezenesulphonamide
- 3-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl) 2-methylbenezenesulphonamide
- 2-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benezenesulphonamide
- 3-Chloro-*N*-(3-methoxy-5-methyl-2-pyrazinyl)benezenesulphonamide
- 4-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benezenesulphonamide
- 2,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benezenesulphonamide
- 3,4-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)benezenesulphonamide
- N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-trifluoromethoxybenezenesulphonamide
- 3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
- 2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 4-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- N-(5-Chloro-3-methoxy-2-pyrazinyl)-2,4-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[3,5-dimethoxy-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[3-methoxy-5-(1-pyrrolinyl)-2-pyrazinyl]benzenesulphonamide
  - 3-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-methylbenzenesulphonamide
- 2,3-Dichloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2-Chloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 3-Chloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 4-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,4-Dichloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 3,4-Dichloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-(3-methoxy-5,6-dimethyl-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-(6-chloro-3,5-dimethoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-[6-chloro-3-methoxy-5-(4-morpholinyl)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[6-chloro-5-(2-hydroxyethylamino)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[6-chloro-5-dimethylamino-3-methoxy-2-pyrazinyl]benzenesulphonamide

- 2,3-Dichloro-N-[6-chloro-3-methoxy-5-(2-methoxyethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[6-chloro-5-hydroxy-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[6-methoxy-5-([2,2']bipyrazinylyl)]benzenesulphonamide
- 4-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]benzoic-acid
- 2,3-Dichloro-*N*-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-*N*-{6-chloro-3-methoxy-5-([2-methoxyethyl)amino]-2-pyrazinyl} benzenesulphonamide
- *N*-{2-[3-Chloro-5-(2,3-dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylamino]ethyl}acetamide
- 2,3-Dichloro-*N*-[5-(4-hydroxymethyl-1-piperidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-cyano-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-(6-chloro-3-methoxy-5-methylamino-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-(3-methoxy-5-methylsulphanyl-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-[5-(2,4-difluorophenyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- -[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid methyl ester
- [5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetic acid
- 2,3-Dichloro-N-[5-(2-chlorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Diehloro-*N*-[6-chloro-5-(3-hydroxy-1-azetidinyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-methyl-3-(1-oxy-3-pyrazinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-[5-chloro-3-(4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(1-oxy-4-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-(2-methylsulphanylethoxy)-2-pyrazinyl]benzenesulphonamide
- N-(3-Butoxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(2-methyl-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(6-methyl-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(1-oxy-2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-methylbenzenesulphonamide
- 3-Chloro-N-[5-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-fluorobenzenesulphonamide
- 2.3-Dichloro-N-[5-chloro-3-(4-methoxyphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
- N-[5-Bromo-6-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide

- 2,3-Dichloro-N-[6-chloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- N-[5 (2-Aminoethylsulphanyl) 3-(2-pyridinylmethoxy) 2-pyrazinyl] 2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(6-methoxy-3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
- N-[3-(3-Bromophenylmethoxy)-5-chloro 2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- 3-[6-Chloro-3-(2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid methyl ester
- 3-[6-Chloro-3 (2,3-dichlorobenzenesulphonylamino)-2-pyrazinyloxymethyl]benzoic acid
- 2,3-Dichloro-*N*-[5-chloro-3-(3-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-(3-methylaminomethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-{3-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro *N* [5-chloro 3 (4-hydroxymethylphenylmethoxy) 2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-{4-([2-hydroxyethylamino]methyl)phenylmethoxy}-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[3-(4-hydroxymethylphenylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-*N*-[5-chloro-3-(2-hydroxymethylphenylmethoxy)-2-pyrazinyllbenzenesulphonamide
- 5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxypyrazine-2-carboxylic acid, methyl ester
- 2,3-Dichloro-N-[5-(1-hydroxy-1-methylethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- N-[5-(2-Aminoethoxy)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-{5-[(2-Aminoethyl)thio]-6-chloro-3-methoxy-2-pyrazinyl}-2,3-dichlorobenzenesulfonamide
- 3-[(5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-methoxy-2-pyrazinyl)thio]propanoic acid, methyl ester
- 2,3-Dichloro-N-[5-bromo-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
- 5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-3-methylpyrazine-2-carboxylic a<u>ciied</u>, methyl ester
- 2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-[5,6-dichloro-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide

Page 11

```
3-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-fluorobenzenesulphonamide
3-Chloro-2-fluoro-N-[3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
3-{[(2,3-Dichlorophenyl)sulphonyl]amino}pyrazine-2-carboxylic acid, methyl ester
N-(5-Bromo-6-chloro-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
3-Chloro-5-{[(2,3-dichlorophenyl)sulphonyl]amino}-6-methoxypyrazine-2-carboxylic acid,
   methyl ester
2,3-Dichloro-N-[6-chloro-5-(hydroxymethyl)-3-methoxypyrazin-2-yl]benzenesulphonamide
2,3-Dichloro-N-{3-[(6-methoxy-3-pyridinyl)methoxy]-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-[6-chloro-3-methoxy-5-(methoxymethyl)-2-pyrazinyl]benzenesulphonamide
2-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-3-fluorobenzenesulphonamide
2-Chloro-3-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
2-Chloro-3-methoxy-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide
N-[5-Bromo-3-[(2S)-2-pyrrolidinylmethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
5-(2,3-Dichlorobenzenesulphonylamino)-6 (3-pyridinylmethoxy)pyrazine-2-carboxylic acid,
   methyl ester
5-{[(2,3-Dichlorophenyl)sulphonyl]amino}-6-(3-pyridinylmethoxy)-2-pyrazinecarboxamide
2,3-Dichloro-N-[5-(4-pyridinyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-(hydroxymethyl)-3-(3-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-[5-(hydroxymethyl)-3-methoxy)-2-pyrazinyl]benzenesulphonamide
4-Amino-2.3-dichloro-N-(5-chloro-3-methoxy-2-pyrazinyl)benzenesulphonamide
N-(5-Allyloxy-3-methoxy-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
2,3-Dichloro-N-[5-(3-hydroxy-1-propynyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
N-{3-[(5-Bromo-3-pyridinyl)methoxy]-5-chloro-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
2.3-Dichloro-N-[5-chloro-3-{[6-(hydroxymethyl) 2-pyridinyl]methoxy}-2-
   pyrazinyl]benzenesulphonamide
2,3-Dichloro-N-{5-chloro-3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl}benzenesulphonamide
2,3-Dichloro-N-{3-[(2-methyl-4-oxazolyl)methoxy]-2-pyrazinyl} benzenesulphonamide
N-[5-Bromo-3-(phenylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(2-cyclopropylethoxy)pyrazinyl]-2,3-dichlorobenzenesulphonamide
N-[5-Bromo-3-(3-thienylmethoxy)pyrazinyl]-2,3-dichlorobenzenesulphonamide
N {5-Bromo-3-[(2-methyl-3-furanyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-f(3-furanyl)methoxy}-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(4-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
N-{5-Bromo-3-[(3-fluorophenyl)methoxy]-2-pyrazinyl}-2,3-diehlorobenzenesulphonamide
```

```
N-{5-Bromo-3-[3-(2-pyridinyl)propoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
```

- N-[5-Bromo-3-(pentyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(propyloxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(2-ethoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(2-fluoroethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-{5-Bromo-3-[2-(1H-imidazol-1-yl)ethoxy]-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
- N-{5-Bromo-3-[3-(3-pyridinyl)propoxy]-2-pyrazinyl}-2.3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-[2-(methylamino)ethoxy]-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-{5-Bromo-3-[3-(4-hydroxyphenyl)propoxy}-2-pyrazinyl}-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(2-phenoxyethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(cyclopropylmethoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- N-[5-Bromo-3-(3-phenoxypropoxy)-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-(5-ethoxy-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5-([1.2,4]-1-triazolyl)-2-pyrazinyl]benzenesulphonamide
- 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]-*N*-methylacetamide
- 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinylsulphanyl]acetamide
- 2,3-Dichloro N [5-(4-fluorobenzylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[5-cyanomethylsulphanyl-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro *N*-[3-methoxy-5-([1,2,4]-3-oxadiazolylmethylsulphanyl)-2-pyrazinyl]benzenesulphonamide
- N-[5-(2-Aminoethylsulphanyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5 (5-methyl-3-isoxazolylmethoxy))-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N* [5-(5-dimethylaminomethyl-2-furanylmethoxy)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- N-[5-Bromo-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-2,3-dichloro-benzenesulphonamide
- 2,3-Dichloro-N-[5-(2-hydroxyethylsulphanyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-{5-[2-(ethylureido)ethylsulphanyl]-3-methoxy-2-pyrazinyl} benzenesulphonamide
- 2,3-Dichloro-*N*-[3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide

- 2,3-Dichloro N [6-chloro-3-(5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[6-chloro-3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3 (5-dimethylaminomethyl-2-furanylmethoxy)-2-pyrazinyllbenzenesulphonamide
- 2,3-Dichloro-N-[3-(5-methylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]benzenesulphonamide
- N-(5-Bromo-3-methoxypyrazinyl)-2-cyanobenzenesulphonamide
- N-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-4-fluorobenzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5 (4-morpholinylmethyl)-2-pyrazinyl]benzenesulphonamide
- N-(3-Allyloxy-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-(2-propynyloxy)-2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-N-[3-(2-propynyloxy)-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-(5-cyano-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-*N*-{3-methoxy-5-[(2S)-pyrrolidin-2-ylmethoxy]-2-pyrazinyl}benzenesulfonamide hydrochloride
- 2,3-Dichloro-*N*-{6-chloro-3-methoxy-5-[(2R)-2-pyrrolidinylmethoxy]-2-pyrazinyl} benzenesulphonamide Hydrochloride
- 2,3-Dichloro-*N*-[3-methoxy-5-(2-pyridinylmethoxy)-2-pyrazinyl]benzenesulphonamide Hydrochloride
- 2,3-Dichloro-N-(3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5-(1H-1,2,4-triazol-1-ylmethyl)-2-pyrazinyl]benzenesulphonamide
- N (3-(5-Aminomethyl-2-furanylmethoxy)-5-chloro-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
- N (3-(5-Aminomethyl-2-furanylmethoxy)-2-pyrazinyl)-2,3-dichlorobenzenesulphonamide
- 2,3-Dichloro-N-[3-methoxy-5-(2-propyn-1-yloxy)-2-pyrazinyl]benzenesulphonamide
- {[5-(2,3-Dichlorophenylsulfonylamino)-6-methoxy-2-pyrazinyl]oxy}acetic acid, methyl ester
- N-[5-(2,3-Dichlorophenylsulphonylamino)-6-methoxy-2-pyrazinyl]-2-hydroxyacetamide
- 6-(2,3-Dichlorophenylsulphonylamino)-5-methoxy-2-pyrazinecarboxylic acid, methyl ester
- 2,3-Dichloro-N-[6-(hydroxymethyl)-3-methoxy-2-pyrazinyl]benzenesulphonamide
- 2.3-Dichloro-N-(5-methanesulphonyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2-[5-(2,3-Dichlorobenzenesulphonylamino)-6-methoxy-2-pyrazinyloxy]-N,N-diethyl-acetamide

2,3-Dichloro-*N*-{5-[2-(dimethylamino)ethylsulphanyl]-3-methoxy-2-pyrazinyl} benzenesulphonamide

- 2,3-Dichloro-N-(5-difluoromethyl-3-methoxy-2-pyrazinyl)benzenesulphonamide
- 2,3-Dichloro-4-fluoro-N-(3-methoxy-2-pyrazinyl)benzenesulphonamide, or
- 2,3-Dichloro-N-{5-chloro-3-[1-(cyclopropyl)ethoxy]-2-pyrazinyl} benzenesulphonamide
- 2,3-Dichloro-N-[5-chloro-3-(5-formyl-2-furanylmethoxy) 2-pyrazinyl]benzenesulphonamide
- 2,3-Dichloro-*N*-[5-chloro-3-(5-cyclopropylaminomethyl-2-furanylmethoxy)-2-pyrazinyl]-benzenesulphonamide

N-[5,6-bis-(Hydroxymethyl)-3-methoxy-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide N-[3-[(2-amino-4-oxazolyl)methoxy]-5-chloro-2-pyrazinyl]-2,3-dichlorobenzenesulphonamide or a and pharmaceutically acceptable salt salts and solvates-thereof.

Claim 7 (withdrawn: currently amended): A process for the preparation of compound (I) which comprises:

(a) reaction of a compound of formula (II):

where R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):

$$\begin{array}{c|c}
R^{1} & O \\
 & S = O \\
 & LG
\end{array}$$
(III)

where  $R^1$ ,  $R^2$  and  $R^3$  are as defined in formula (I) or are protected derivatives thereof and LG is a leaving group, or

(b) for compounds where R<sup>4</sup> is C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;

C<sub>3-6</sub> alkenyloxy or C<sub>3-6</sub> alkynyloxy where either may be optionally substituted with hydroxy or NR<sup>14</sup>R<sup>15</sup>;

OC<sub>1-6</sub>-alkyl-X-C<sub>1-6</sub>-alkyl where the alkyl groups may form a 3-6 membered saturated ring; OC<sub>1-6</sub>-alkylR<sup>1+</sup>, or OC<sub>2-6</sub>-alkyl-X-R<sup>1+</sup> where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>, SR<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>, S(O)<sub>R</sub><sup>13</sup>; or

OCL6-alkyIR16;

treating a compound of the formula (VI), where LG is a leaving group:

$$R^{5}$$
 $R^{6}$ 
 $N$ 
 $NH$ 
 $O=S=O$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $(VI)$ 

with a compound of formula  $R^4$ -H (V) in the presence of a suitable base, or

(c) for compounds of structure (l), where R<sup>s</sup> is an optionally substituted aryl or heteroaryl ring as defined above, reacting a compound of formula (XI) or (VII) where LG is a leaving group with an aryl or heteroaryl boronic acid in the presence of a palladium catalyst and a suitable base at elevated temperature:

and optionally thereafter process (a) or; (b) or (c)

- removing any protecting groups,
- converting a compound of formula (I) to a further compound of formula (I)
- forming a pharmaceutically acceptable salt.

Claim 8 (currently amended): A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 9 (withdrawn: currently amended): A process for the preparation of a pharmaceutical composition as claimed in claim 82 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

## Claim 10 (cancelled).

Claim 11 (withdrawn: currently amended): A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (IB), or a pharmaceutically acceptable salt or solvate-thereof:

Application No.: 10/501,510

Page 17

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{4}$ 
 $R^{5}$ 
(IB)

in which:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, <u>chlorine</u>, <u>fluorine</u>, <u>bromine</u> <u>halogen</u>, <u>or</u> cyano, <del>CF<sub>3</sub>, or</del> <del>C<sub>1-6</sub> alkyl</del>;

R<sup>4</sup> is halogen, CO<sub>2</sub>R<sup>12</sup><u>or</u>, C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;

C<sub>3-6</sub>-alkenyloxy or C<sub>3-6</sub>-alkynyloxy where either may be optionally substituted with hydroxy or NR<sup>14</sup>R<sup>15</sup>:

OC<sub>1-6</sub>-alkyl-X-C<sub>1-6</sub> alkyl-where the alkyl groups may form a 3-6 membered saturated ring; OC<sub>1-6</sub>-alkylR<sup>11</sup>, or OC<sub>2-6</sub> alkyl-X-R<sup>11</sup> where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen,  $NR^{14}R^{15}$ ,  $SR^{13}$ ,  $S(O)_2R^{13}$ ,  $S(O)_R^{13}$ ;

OCL6-alkyIR16:

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, cyano, halogen, CO2R<sup>12</sup>, CONR<sup>14</sup>R<sup>15</sup>;

C<sub>1-6</sub> alkyl optionally substituted by hydroxy, NR<sup>14</sup>R<sup>15</sup>, or 1-3 fluorines;

C<sub>1-6</sub>-alkyIR<sup>11</sup>-or XCH(R<sup>14</sup>)C<sub>1-6</sub>-alkyl or XCH(R<sup>16</sup>)C<sub>1-6</sub>-alkyl where the alkyl-group may be optionally substituted with 1-3 groups selected from hydroxy, and NR<sup>14</sup>R<sup>15</sup>;

 $NR^{14}R^{15}$ ;  $N(R^{11})R^{11}$ ;  $X - (CH_2)qNR^{14}R^{15}$ ;  $(CH_2)nNR^{14}R^{15}$ ;

 $C_{3-6}$  alkynyl or  $C_{3-6}$  alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O;

 $R^{++}; X-R^{++}; X-R^{12}; X-C_{++}alkylR^{++}; X-R^{++}; X-(CH_2)nCO_2R^{12}; X-(CH_2)nCONR^{14}R^{15};$ 

 $X-(CH_2)nR^{H_2}$ ;  $X-(CH_2)nCN$ ;  $X-(CH_2)qOR^{12}$ ;  $(CH_2)nOR^{12}$ ;

(CH<sub>2</sub>)n-X-R<sup>11</sup>; X-(CH<sub>2</sub>)qNHC(O)NHR<sup>12</sup>; X-(CH<sub>2</sub>)qNHC(O)R<sup>12</sup>;

 $X-(CH_2)qNHS(O)_2R^{12}; -X-(CH_2)qNHS(O)_2R^{11}; \ X-C_{3-6}alkenyl; \ X-C_{3-6}alkynyl;$ 

n is 1,2,3,4 or 5; q is 2, 3, 4, 5 or 6; X is NR<sup>13</sup>, O, S, S(O), S(O)<sub>2</sub>;

- R<sup>+1</sup>-is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR<sup>+1</sup>R<sup>+5</sup>, C(O)OR<sup>+2</sup>, hydroxy, =O, =S, CN, NO<sub>2</sub> NR<sup>+4</sup>R<sup>+5</sup>, X(CH<sub>2</sub>)qNR<sup>+4</sup>R<sup>+5</sup>, (CH<sub>2</sub>)nNR<sup>+4</sup>R<sup>+5</sup>, (CH<sub>2</sub>)nOH, SR<sup>+3</sup>, S(O)R<sup>+3</sup>, S(O)<sub>2</sub>R<sup>+3</sup> C<sub>1-6</sub> alkyl-X-C<sub>1-6</sub> alkyl-or C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>+4</sup>R<sup>+5</sup>, SR<sup>+3</sup>, S(O)R<sup>+3</sup>, S(O)<sub>2</sub>R<sup>+3</sup>;
- R<sup>12</sup> and R<sup>13</sup> are independently hydrogen or C<sub>1-6</sub> alkyl where the alkyl group may be substituted with 1-3 fluorine atoms; or may form a saturated 3-6 membered ring; and
- R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl or (CH<sub>2</sub>)qOH<sub>2</sub>,
  - or R<sup>14</sup>-and R<sup>15</sup>-together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl-OH, or hydroxy; and
- R<sup>16</sup>-is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O.
- Claim 12 (withdrawn: currently amended): AThe method according to claim 11 in which the chemokine receptor belongs to the CCR chemokine receptor subfamily.
- Claim 13 (withdrawn: currently amended): <u>The</u>A method according to claim 11 or 12 in which the chemokine receptor is the CCR4 receptor.

Claim 14 (withdrawn: currently amended): A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (IB), or a pharmaceutically acceptable salt-or solvate thereof; as defined in claim 11.

$$\begin{array}{c|c}
R^{1} & O \\
R^{2} & S = O \\
R^{3} & H & N & R^{6} \\
\hline
R^{4} & N & R^{5}
\end{array}$$
(IB)

in which:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, chlorine, fluorine, bromine or cyano;

R<sup>4</sup> is halogen, CO<sub>2</sub>R<sup>12</sup> or C<sub>1-6</sub> alkoxy where the alkyl group may be substituted with 1-3 fluorine atoms or a cyano group;

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, cyano, halogen, CO2R<sup>12</sup>, CONR<sup>14</sup>R<sup>15</sup>;

C<sub>1-6</sub> alkyl optionally substituted by hydroxy, NR<sup>14</sup>R<sup>15</sup>, or 1-3 fluorines;

 $C_{3-6}$  alkynyl or  $C_{3-6}$  alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =0;

X-R<sup>12</sup>; X-(CH<sub>2</sub>)nCO<sub>2</sub>R<sup>12</sup>; X-(CH<sub>2</sub>)nCONR<sup>14</sup>R<sup>15</sup>;

X-(CH<sub>2</sub>)nCN; X-(CH<sub>2</sub>)qOR<sup>12</sup>; (CH<sub>2</sub>)nOR<sup>12</sup>:

 $X-(CH_2)qNHC(O)NHR^{12}$ ;  $X-(CH_2)qNHC(O)R^{12}$ ;

 $X-(CH_2)qNHS(O)_2R^{12}; X-C_{3-6}alkenyl; X-C_{3-6}alkynyl;$ 

n is 1 2 3 4 or 5

q is 2, 3, 4, 5 or 6;

 $X \text{ is } NR^{13}, O, S, S(O), S(O)_2$ 

 $R^{12}$  and  $R^{13}$  are independently hydrogen or  $C_{1-6}$  alkyl where the alkyl group may be substituted with 1-3 fluorine atoms; and

R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub> alkyl or (CH<sub>2</sub>)qOH.

Claim 15 (withdrawn: currently amended): A <u>The</u> method according to claim 14, wherein the disease is asthma.

Claim 16 (**new**): A compound according to claim 1 which is 2,3-dichloro-*N*-(3-methoxy-2-pyrazinyl)benzenesulphonamide or a pharmaceutically acceptable salt thereof.

Claim 17 (**new**): A compound according to claim 1 which is 2,3-dichloro-*N*-[5-(hydroxymethyl)-3-methoxy-6-methyl-2-pyrazinyl)benzenesulphonamide or a pharmaceutically acceptable salt thereof

Claim 18 (**new**): A compound according to claim 1 which is 2,3-dichloro-*N*-[6-chloro-5-(hydroxymethyl)-3-methoxypyrazin-2-yl]benzenesulphonamide or a pharmaceutically acceptable salt thereof.

Claim 19 (**new**): A compound according to claim 1 which is 2,3-dichloro-*N*-[6-chloro-3-methoxy-5-(methoxymethyl)-2-pyrazinyl]benzenesulphonamide or a pharmaceutically acceptable salt thereof.

Claim 20 (**new**): A compound according to claim 1 which is 2,3-dichloro-*N*-[5-(hydroxymethyl)-3-methoxy)-2-pyrazinyl]benzenesulphonamide or a pharmaceutically acceptable salt thereof.